$SUND
Sundance Strategies, Inc. Stock $sund

$sund Overview Financials Valuation SEC Filings Company Website

2013 Q3 Form 10-Q Financial Statement

#000101041213000226 Filed on August 12, 2013

Income Statement

Concept	2013 Q3	2013 Q2	2012 Q2
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$310.0K	$1.030M	$0.00
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization			$0.00
YoY Change
% of Gross Profit
Operating Expenses	$310.8K	$1.034M	$3.515K
YoY Change		29312.94%	-22.59%
Operating Profit	-$310.8K	-$1.034M	-$3.515K
YoY Change		29312.94%	-22.59%
Interest Expense	$30.71K	$30.07K	$65.00
YoY Change		46166.15%	0.0%
% of Operating Profit
Other Income/Expense, Net	-$30.71K	-$30.05K	-$65.00
YoY Change		46133.85%	0.0%
Pretax Income	-$341.5K	-$1.064M	$0.00
YoY Change
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$341.5K	-$1.064M	-$3.580K
YoY Change		29618.35%	-22.28%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$8.045K	-$25.68K	$0.00
COMMON SHARES
Basic Shares Outstanding	42.26M shares	40.80M shares	11.28M
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q3	2013 Q2	2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$980.0K	$1.260M	$0.00
YoY Change
Cash & Equivalents	$979.6K	$1.259M	$207.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$979.6K	$1.259M	$207.00
YoY Change		607884.06%	-91.1%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$12.71M	$12.10M
YoY Change
Other Assets	$6.414M	$8.573M
YoY Change
Total Long-Term Assets	$12.71M	$12.10M	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$979.6K	$1.259M	$207.00
Total Long-Term Assets	$12.71M	$12.10M	$0.00
Total Assets	$13.69M	$13.36M	$207.00
YoY Change		6451700.48%	-91.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$140.0K	$250.0K	$385.00
YoY Change		64835.06%	-90.35%
Accrued Expenses			$0.00
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$3.000M	$3.000M	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$0.00
YoY Change
Total Short-Term Liabilities	$3.150M	$3.253M	$19.37K
YoY Change	15650.1%	16691.56%	61.88%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.150M	$3.253M	$19.37K
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$3.150M	$3.253M	$19.37K
YoY Change	15650.1%	16691.56%	61.88%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.510M	-$1.169M	-$508.2K
YoY Change		129.96%	1.91%
Common Stock	$794.8K	$11.28M	$11.28K
YoY Change		99871.96%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$10.54M	$10.10M	-$19.16K
YoY Change
Total Liabilities & Shareholders Equity	$13.69M	$13.36M	$207.00
YoY Change		6451700.48%	-91.1%

Cashflow Statement

Concept	2013 Q3	2013 Q2	2012 Q2
OPERATING ACTIVITIES
Net Income	-$341.5K	-$1.064M	-$3.580K
YoY Change		29618.35%	-22.28%
Depreciation, Depletion And Amortization			$0.00
YoY Change
Cash From Operating Activities	-$910.0K	-$6.239M	-$4.990K
YoY Change	9000.0%	124923.35%	805.63%
INVESTING ACTIVITIES
Capital Expenditures			$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$6.952M	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	630.0K	$6.952M	$4.950K
YoY Change	6200.0%	140339.9%	147.5%
NET CHANGE
Cash From Operating Activities	-910.0K	-$6.239M	-$4.990K
Cash From Investing Activities
Cash From Financing Activities	630.0K	$6.952M	$4.950K
Net Change In Cash	-280.0K	$713.1K	-$40.00
YoY Change		-1782875.0%	-102.76%
FREE CASH FLOW
Cash From Operating Activities	-$910.0K	-$6.239M	-$4.990K
Capital Expenditures			$0.00
Free Cash Flow			-$4.990K
YoY Change			805.63%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q2	dei	Amendment Flag AmendmentFlag	false
CY2013Q2	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2013Q2	sund	Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid In Next Twelve Months LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidInNextTwelveMonths	-6136901	USD
CY2013Q2	sund	Life Settlement Contracts Investment Method Expenses Plus Interest To Be Paid Total LifeSettlementContractsInvestmentMethodExpensesPlusInterestToBePaidTotal	-26599992	USD
CY2013Q2	sund	Life Settlement Contracts Investment Method Premiums Paid And Other Expenses LifeSettlementContractsInvestmentMethodPremiumsPaidAndOtherExpenses	20727306	USD
CY2013Q2	sund	Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaid	-67829558	USD
CY2013Q2	sund	Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid After Year Five LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidAfterYearFive	-33185685	USD
CY2013Q2	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2013Q2	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2013Q2	dei	Document Period End Date DocumentPeriodEndDate	2013-06-30
CY2013Q2	dei	Document Type DocumentType	10-Q
CY2013Q2	dei	Entity Central Index Key EntityCentralIndexKey	0001171838
CY2013Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	42261441	shares
CY2013Q2	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2013Q2	dei	Entity Registrant Name EntityRegistrantName	Sundance Strategies, Inc.
CY2013Q2	sund	Capitalized Consultant Fee CapitalizedConsultantFee	300000	USD
CY2013Q2	sund	Fair Value Of Warrants Issued Stock Issuance Costs FairValueOfWarrantsIssuedStockIssuanceCosts	139251	USD
	sund	Fair Value Of Warrants Issued Stock Issuance Costs FairValueOfWarrantsIssuedStockIssuanceCosts	139251	USD
CY2013Q2	sund	Life Insurance Policies Purchased With Debt LifeInsurancePoliciesPurchasedWithDebt		USD
CY2012Q2	sund	Life Insurance Policies Purchased With Debt LifeInsurancePoliciesPurchasedWithDebt		USD
	sund	Life Insurance Policies Purchased With Debt LifeInsurancePoliciesPurchasedWithDebt	2999000	USD
CY2013Q2	sund	Life Settlement Contracts Investment Method Expenses Plus Interest In Next Twelve Months LifeSettlementContractsInvestmentMethodExpensesPlusInterestInNextTwelveMonths	-2113501	USD
CY2013Q2	sund	Life Settlement Contracts Investment Method Expenses Plus Interest To Be Paid After Year Five LifeSettlementContractsInvestmentMethodExpensesPlusInterestToBePaidAfterYearFive	-12528509	USD
CY2013Q2	sund	Life Settlement Contracts Investment Method Expenses Plus Interest To Be Paid In Year Five LifeSettlementContractsInvestmentMethodExpensesPlusInterestToBePaidInYearFive	-2806601	USD
CY2013Q2	sund	Life Settlement Contracts Investment Method Expenses Plus Interest To Be Paid In Year Four LifeSettlementContractsInvestmentMethodExpensesPlusInterestToBePaidInYearFour	-3051680	USD
CY2013Q2	sund	Life Settlement Contracts Investment Method Expenses Plus Interest To Be Paid In Year Three LifeSettlementContractsInvestmentMethodExpensesPlusInterestToBePaidInYearThree	-3169934	USD
CY2013Q2	sund	Life Settlement Contracts Investment Method Expenses Plus Interest To Be Paid In Year Two LifeSettlementContractsInvestmentMethodExpensesPlusInterestToBePaidInYearTwo	-2929767	USD
CY2013Q2	sund	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercised Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm2
CY2013Q2	sund	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresWeightedAverageGrantDateFairValue		pure
CY2013Q2	sund	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2	P4Y9M18D
CY2013Q2	sund	Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid In Year Five LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidInYearFive	-6513716	USD
CY2013Q2	sund	Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid In Year Four LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidInYearFour	-7001455	USD
CY2013Q2	sund	Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid In Year Three LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidInYearThree	-7724934	USD
CY2013Q2	sund	Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid In Year Two LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidInYearTwo	-7266867	USD
CY2013Q2	sund	Life Settlement Contracts Portion Of Pledge Agreement Paid In Cash LifeSettlementContractsPortionOfPledgeAgreementPaidInCash	3000000	USD
CY2013Q2	sund	Life Settlement Contracts Purchased Through Pledge Agreement LifeSettlementContractsPurchasedThroughPledgeAgreement	5999000	USD
CY2013Q2	sund	Maximum Number Of Common Shares Offered Through Private Placement MaximumNumberOfCommonSharesOfferedThroughPrivatePlacement	3000000	shares
CY2013Q2	sund	Number Of Shares Of Restricted Stock Sold Through Private Placement NumberOfSharesOfRestrictedStockSoldThroughPrivatePlacement	1464000	shares
CY2013Q2	sund	Return Of Premium Provisions On Life Settlement Contracts ReturnOfPremiumProvisionsOnLifeSettlementContracts	267801	USD
CY2013Q2	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cancelled Or Expired In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledOrExpiredInPeriodIntrinsicValue		USD
CY2013Q2	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue		USD
CY2013Q2	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms	P1Y11M1D
CY2013Q2	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageRemainingContractualTerms
CY2013Q2	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms	P1Y11M1D
CY2013Q2	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Intrinsic Value Extended ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValueExtended		USD
CY2013Q2	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberExercised	70000	shares
CY2013Q2	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedOutstandingWeightedAverageExercisePrice	5
CY2013Q1	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedOutstandingWeightedAverageExercisePrice
CY2013Q2	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Exercise Price Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceExercised	5
CY2013Q2	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Exercise Price Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceForfeitures
CY2013Q2	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Exercise Price Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceGranted	5
CY2013Q2	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExercisable	1.96
CY2013Q2	sund	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue	0.96	pure
CY2013Q2	sund	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue		pure
CY2013Q2	sund	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue	0.96	pure
CY2013Q1	sund	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue		pure
CY2013Q2	sund	Stock Issuance Costs Payable StockIssuanceCostsPayable	560000	USD
CY2013Q2	sund	Total Cash Consideration That Would Be Paid By Company If All Net Insurance Benefits Are Provided Under Asset Transfer Agreement TotalCashConsiderationThatWouldBePaidByCompanyIfAllNetInsuranceBenefitsAreProvidedUnderAssetTransferAgreement	8000000	USD
CY2013Q2	sund	Total Consideration That Would Be Paid By Company If All Net Insurance Benefits Are Provided Under Asset Transfer Agreement TotalConsiderationThatWouldBePaidByCompanyIfAllNetInsuranceBenefitsAreProvidedUnderAssetTransferAgreement	20000000	USD
CY2013Q2	sund	Total Notes Payable That Would Be Issued By Company If All Net Insurance Benefits Are Provided Under Asset Transfer Agreement TotalNotesPayableThatWouldBeIssuedByCompanyIfAllNetInsuranceBenefitsAreProvidedUnderAssetTransferAgreement	12000000	USD
CY2013Q2	sund	Value Of Net Insurance Benefits Required To Be Delivered Per Asset Transfer Agreement ValueOfNetInsuranceBenefitsRequiredToBeDeliveredPerAssetTransferAgreement	400000000	USD
CY2013Q2	sund	Working Capital WorkingCapital	-1994166	USD
CY2013Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	246252	USD
CY2013Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	89082	USD
CY2013Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	11234575	USD
CY2013Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	3850257	USD
CY2013Q2	us-gaap	Assets Assets	13355227	USD
CY2013Q1	us-gaap	Assets Assets	6844417	USD
CY2013Q2	us-gaap	Assets Current AssetsCurrent	1258527	USD
CY2013Q1	us-gaap	Assets Current AssetsCurrent	545417	USD
CY2013Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	12096700	USD
CY2013Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	6299000	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1258527	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	545417	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue		USD
CY2013Q2	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	713110	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1258527	USD
CY2013Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	5.00
CY2013Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	70000	shares
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2013Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42261441	shares
CY2013Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40797441	shares
CY2013Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42261441	shares
CY2013Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40797441	shares
CY2013Q2	us-gaap	Common Stock Value CommonStockValue	42262	USD
CY2013Q1	us-gaap	Common Stock Value CommonStockValue	40798	USD
CY2013Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2999000	USD
CY2013Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.04	pure
CY2013Q2	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2013-12-31
CY2013Q2	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div style="WIDTH: 660px"><!--StartFragment--> <p style="MARGIN: 0px; text-align: justify"><strong>(2) NEW ACCOUNTING PRONOUNCEMENTS</strong></p> <p style="MARGIN: 0px; text-align: justify"><br /> </p> <p style="MARGIN: 0px; text-align: justify; TEXT-INDENT: 48px">The Company has reviewed recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operations, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements.</p> <!--EndFragment--></div> </div>
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
CY2013Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y
CY2013Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	409016	USD
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	915075	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	968977	USD
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1063917	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1168568	USD
CY2013Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2013Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2830	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	78498	USD
CY2013Q2	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	5797700	USD
CY2012Q2	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets		USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	5797700	USD
CY2013Q2	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets		USD
CY2012Q2	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets		USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	3300000	USD
CY2013Q2	us-gaap	Interest Expense InterestExpense	30073	USD
	us-gaap	Interest Expense InterestExpense	36650	USD
CY2013Q2	us-gaap	Interest Income Other InterestIncomeOther	21	USD
	us-gaap	Interest Income Other InterestIncomeOther	21	USD
CY2013Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	36650	USD
CY2013Q2	us-gaap	Liabilities Liabilities	3252693	USD
CY2013Q1	us-gaap	Liabilities Liabilities	3095523	USD
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13355227	USD
CY2013Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6844417	USD
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	41280078	shares
CY2013Q2	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts LifeSettlementContractsInvestmentMethodNumberOfContracts	22	pure
CY2013Q2	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing After Year Five LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingAfterYearFive	18	pure
CY2013Q2	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Next Twelve Months LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInNextTwelveMonths	0	pure
CY2013Q2	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Five LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearFive	4	pure
CY2013Q2	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Four LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearFour	0	pure
CY2013Q2	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1		USD
CY2012Q2	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1		USD
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	15195	USD
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3252693	USD
CY2013Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3095523	USD
CY2013Q2	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	6299000	USD
CY2013Q1	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	6299000	USD
CY2013Q2	us-gaap	Life Settlement Contracts Investment Method Face Value LifeSettlementContractsInvestmentMethodFaceValue	129306734	USD
CY2013Q2	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing After Year Five LifeSettlementContractsInvestmentMethodFaceValueMaturingAfterYearFive	113306734	USD
CY2013Q2	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Next Twelve Months LifeSettlementContractsInvestmentMethodFaceValueMaturingInNextTwelveMonths		USD
CY2013Q2	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Year Five LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearFive	16000000	USD
CY2013Q2	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Year Four LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearFour		USD
CY2013Q2	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Year Three LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearThree		USD
CY2013Q2	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Year Two LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearTwo		USD
CY2013Q2	us-gaap	Life Settlement Contracts Investment Method Five Year Disclosure Premiums To Be Paid LifeSettlementContractsInvestmentMethodFiveYearDisclosurePremiumsToBePaid	-41229566	USD
CY2013Q2	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Three LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearThree	0	pure
CY2013Q2	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Two LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearTwo	0	pure
CY2013Q2	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid After Year Five LifeSettlementContractsInvestmentMethodPremiumsToBePaidAfterYearFive	-20657176	USD
CY2013Q2	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Next Twelve Months LifeSettlementContractsInvestmentMethodPremiumsToBePaidInNextTwelveMonths	-4023400	USD
CY2013Q2	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Year Five LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearFive	-3707115	USD
CY2013Q2	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Year Four LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearFour	-3949775	USD
CY2013Q2	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Year Three LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearThree	-4555000	USD
CY2013Q2	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Year Two LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearTwo	-4337100	USD
CY2013Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6951775	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10820515	USD
CY2012Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		USD
CY2013Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6238665	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9561988	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-1063917	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1168568	USD
CY2013Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-30052	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-36629	USD
CY2013Q2	us-gaap	Notes Payable Current NotesPayableCurrent	2999000	USD
CY2013Q1	us-gaap	Notes Payable Current NotesPayableCurrent	2999000	USD
CY2013Q2	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	3441	USD
CY2013Q1	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	3441	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	1033865	USD
	us-gaap	Operating Expenses OperatingExpenses	1131939	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1033865	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1131939	USD
CY2013Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5797700	USD
CY2013Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent		USD
CY2013Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4000	USD
CY2013Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4000	USD
CY2013Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	400000	USD
CY2012Q2	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments		USD
CY2013Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2013Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2013Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q2	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q1	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6951775	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10820515	USD
CY2013Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	7320000	USD
CY2013Q2	us-gaap	Professional Fees ProfessionalFees	118790	USD
	us-gaap	Professional Fees ProfessionalFees	162962	USD
CY2013Q2	us-gaap	Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock	5735	USD
CY2013Q1	us-gaap	Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock	37510	USD
CY2013Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1168568	USD
CY2013Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-104651	USD
CY2013Q2	us-gaap	Revenues Revenues		USD
	us-gaap	Revenues Revenues		USD
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.77
CY2013Q2	us-gaap	Share Based Compensation ShareBasedCompensation	625782	USD
CY2013Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding		USD
CY2013Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding		USD
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	70000	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.96
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.96
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P1Y11M1D
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	70000	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber		shares
CY2013Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	4536675	USD
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1072500	shares
CY2013Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y9M18D
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		USD
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue	463029
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1785000	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.96
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	7550550	USD
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		USD
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1785000	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber		shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.77
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2013Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y9M18D
CY2013Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2013Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.77
CY2013Q2	us-gaap	Share Price SharePrice	5.00
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	10102534	USD
CY2013Q1	us-gaap	Stockholders Equity StockholdersEquity	3748894	USD
CY2013Q2	us-gaap	Stock Issued1 StockIssued1		USD
CY2012Q2	us-gaap	Stock Issued1 StockIssued1		USD
	us-gaap	Stock Issued1 StockIssued1	37510	USD
CY2013Q2	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2013Q2	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	625782	USD
CY2012Q2	us-gaap	Stock Option Plan Expense StockOptionPlanExpense		USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	625782	USD

Files In Submission

Name	View Source	Status
0001010412-13-000226-index-headers.html	Edgar Link	pending
0001010412-13-000226-index.html	Edgar Link	pending
0001010412-13-000226.txt	Edgar Link	pending
0001010412-13-000226-xbrl.zip	Edgar Link	pending
ex311.htm	Edgar Link	pending
ex312.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
qtr1063013lwbclean6includesa.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R1.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R10.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R11.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R12.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R13.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R14.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R15.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R16.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R17.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R18.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R19.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R2.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R20.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R21.xml	Edgar Link	unprocessable
R22.htm	Edgar Link	pending
R22.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R23.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
R24.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R25.xml	Edgar Link	unprocessable
R26.htm	Edgar Link	pending
R26.xml	Edgar Link	unprocessable
R27.htm	Edgar Link	pending
R27.xml	Edgar Link	unprocessable
R28.htm	Edgar Link	pending
R28.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R29.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R3.xml	Edgar Link	unprocessable
R30.htm	Edgar Link	pending
R30.xml	Edgar Link	unprocessable
R31.htm	Edgar Link	pending
R31.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R4.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R5.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R6.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R7.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R8.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
R9.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
stockholderletterlwbclean001.jpg	Edgar Link	pending
stockholderletterlwbclean208.htm	Edgar Link	pending
sund-20130630.xml	Edgar Link	completed
sund-20130630.xsd	Edgar Link	pending
sund-20130630_cal.xml	Edgar Link	unprocessable
sund-20130630_def.xml	Edgar Link	unprocessable
sund-20130630_lab.xml	Edgar Link	unprocessable
sund-20130630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SUND
Sundance Strategies, Inc. Stock $sund

2013 Q3 Form 10-Q Financial Statement

#000101041213000226 Filed on August 12, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SUND Sundance Strategies, Inc. Stock $sund

2013 Q3 Form 10-Q Financial Statement

#000101041213000226 Filed on August 12, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SUND
Sundance Strategies, Inc. Stock $sund